Award
NIH Reporter #1R01AI201701-01
Immunomodulatory Blockade of Type 2 Immunity for Severe Coccidioidomycosis
Recipient
University of California Los Angeles (UCLA)
Award Amount
$787,484.00
Ceiling
$787,484.00
Awarded
August 11, 2026
Identifier
1R01AI201701-01
The project will evaluate dupilumab as an add-on treatment for severe Valley fever and assess its effects on immune responses and clinical outcomes.
Description
A prospective, randomized, placebo-controlled, blinded trial testing whether adjunctive dupilumab with standard antifungal medicines improves outcomes for patients with severe coccidioidomycosis and Type 2 immune skewing.